Overview

Effect of Intravitreally Administered AIV007 in Subjects With nAMD

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration
Phase:
Phase 1
Details
Lead Sponsor:
AiViva BioPharma, Inc.